Survival in BRAF-mutant metastatic melanoma in the real-world setting: results from the Dutch Melanoma Treatment Registry

被引：0

作者：

Schouwenburg, M. ^{[1
]}

Jochems, A. ^{[1
]}

Aarts, M. ^{[2
]}

van den Berkmortel, F. ^{[3
]}

van den Eertwegh, A. ^{[4
]}

Franken, M. ^{[5
]}

Groenewegen, G. ^{[6
]}

de Groot, J-W. ^{[7
]}

Haanen, J. B. A. G. ^{[8
]}

Hospers, G. ^{[9
]}

Kapiteijn, E. ^{[10
]}

Koornstra, R. ^{[11
]}

Kruit, W. ^{[12
]}

Louwman, M. ^{[13
]}

Piersma, D. ^{[14
]}

van Rijn, R. ^{[15
]}

Ten Tije, A. J. ^{[16
]}

Vreugdenhil, G. ^{[17
]}

Wouters, M. ^{[18
]}

van der Hoeven, J. ^{[1
]}

机构：

[1] LUMC, Med Oncol, Leiden, Netherlands

[2] MUMC, Med Oncol, Maastricht, Netherlands

[3] Atrium Med Ctr Parkstad, Med Oncol, Heerlen, Netherlands

[4] Vrije Univ Amsterdam Med Ctr, Med Oncol, Amsterdam, Netherlands

[5] Erasmus Univ, Inst Med Technol Assessment, Med Technol Assessment, Rotterdam, Netherlands

[6] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands

[7] Isala Klin, Med Oncol, Zwolle, Netherlands

[8] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[9] Univ Hosp Groningen UMCG, Med Oncol, Groningen, Netherlands

[10] LUMC, Clin Oncol, Leiden, Netherlands

[11] Radboud Univ Nijmegen, Med Ctr Nijmegen, Med Oncol, Nijmegen, Netherlands

[12] Erasmus MC, Internal Oncol, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands

[13] Netherlands Comprehens Canc Org IKNL, Epidemiol, Utrecht, Netherlands

[14] MST, Med Oncol, Enschede, Netherlands

[15] Med Ctr Leeuwarden, Med Oncol, Leeuwarden, Netherlands

[16] Amphia Ziekenhuis, Med Oncol, Breda, Netherlands

[17] Maxima Med Ctr, Med Oncol, Eindhoven, Netherlands

[18] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.34

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1139P

引用

页数：1

共 50 条

[1] Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
Atkins, Michael B.
Julian, Cristina
Secrest, Matthew H.
Lee, Janet
Abajo-Guijarro, Ana M.
McKenna, Edward
[J]. FUTURE ONCOLOGY, 2022, 18 (18) : 2233 - 2245
[2] IMPROVED SURVIVAL IN PATIENTS WITH ADVANCED MELANOMA IN REAL-WORLD CLINICAL PRACTICE: FIRST RESULTS OF THE DUTCH MELANOMA TREATMENT REGISTRY
Leeneman, B.
Franken, M. G.
Jochems, A.
Schouwenburg, M. G.
Wouters, M. W.
Van den Eertwegh, A. J.
Haanen, J. B.
Van der Hoeven, K. J.
Uyl-de Groot, C. A.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A440 - A441
[3] Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry
Jochems, Anouk
van der Kooij, Monique K.
Fiocco, Marta
Schouwenburg, Maartje G.
Aarts, Maureen J.
van Akkooi, Alexander C.
van den Berkmortel, Franchette W. P. J.
Blank, Christian U.
van den Eertwegh, Alfonsus J. M.
Franken, Margreet G.
de Groot, JanWillem B.
Haanen, John B. A. G.
Hospers, Geke A. P.
Koornstra, Rutger H.
Kruit, Wim H. J.
Louwman, Marieke
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
Vreugdenhil, Gerard
Wouters, Michel W. J. M.
van Zeijl, Michiel C. T.
van der Hoeven, Koos J. M.
Kapiteijn, Ellen
[J]. CANCERS, 2019, 11 (07)
[4] Dabrafenib for treatment of BRAF-mutant melanoma
Kainthla, Radhika
Kim, Kevin B.
Falchook, Gerald S.
[J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 21 - 29
[5] Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes
Schouwenburg, Maartje G.
Jochems, Anouk
Leeneman, Brenda
Franken, Margreet G.
van den Eertwegh, Alfons J. M.
Haanen, John B. A. G.
van Zeijl, Michiel C. T.
Aarts, Maureen J.
van Akkooi, Alexander C. J.
van den Berkmortel, Franchette W. P. J.
Blokx, Willeke A. M.
de Groot, Jan Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Koornstra, Rutger H.
Kruit, Wim H.
Louwman, Marieke W. J.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
Vreugdenhil, Gerard
Wouters, Michel W. J. M.
van der Hoeven, Jacobus J. M.
[J]. MELANOMA RESEARCH, 2018, 28 (04) : 326 - 332
[6] Long-term outcomes in patients with BRAF-mutant advanced melanoma: A real-world study
Amin, A.
Pavlick, A. C.
Lee, C.
Chou, E.
Zhang, Y.
Sakkal, L. A.
Moser, J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1415 - S1416
[7] Current Advances in the Treatment of BRAF-Mutant Melanoma
Patel, Hima
Yacoub, Nour
Mishra, Rosalin
White, Aaron
Yuan, Long
Alanazi, Samar
Garrett, Joan T.
[J]. CANCERS, 2020, 12 (02)
[8] Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting
Pedersen, Sidsel
Larsen, Kirstine Ostenfeld
Christensen, Alex Horby
Svane, Inge Marie
Zerahn, Bo
Ellebaek, Eva
[J]. ACTA ONCOLOGICA, 2022, 61 (01) : 45 - 51
[9] Evaluation of treatment patterns in patients with BRAF-mutant cutaneous melanoma in adjuvant setting in real practice.
Samoylenko, Igor
Stroganova, Anna
Shakhray, Ekaterina
Orlova, Kristina V.
Akhmetianova, Angelina
Demidov, Lev V.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Menzies, Alexander M.
Long, Georgina V.
[J]. CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2035 - 2043

← 1 2 3 4 5 →